ATE554750T1 - Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen - Google Patents

Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen

Info

Publication number
ATE554750T1
ATE554750T1 AT98908884T AT98908884T ATE554750T1 AT E554750 T1 ATE554750 T1 AT E554750T1 AT 98908884 T AT98908884 T AT 98908884T AT 98908884 T AT98908884 T AT 98908884T AT E554750 T1 ATE554750 T1 AT E554750T1
Authority
AT
Austria
Prior art keywords
hydrophobic pharmaceutical
formulations
active ingredients
pharmaceutical active
preparations containing
Prior art date
Application number
AT98908884T
Other languages
English (en)
Inventor
Narmada Shenoy
Gregory Wagner
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE554750T1 publication Critical patent/ATE554750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98908884T 1997-03-05 1998-03-04 Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen ATE554750T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3987097P 1997-03-05 1997-03-05
US4125197P 1997-03-18 1997-03-18
PCT/US1998/004134 WO1998038984A2 (en) 1997-03-05 1998-03-04 Formulations for hydrophobic pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE554750T1 true ATE554750T1 (de) 2012-05-15

Family

ID=26716539

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908884T ATE554750T1 (de) 1997-03-05 1998-03-04 Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen

Country Status (10)

Country Link
US (2) US6248771B1 (de)
EP (1) EP1014953B1 (de)
JP (1) JP4713698B2 (de)
AT (1) ATE554750T1 (de)
AU (1) AU743024B2 (de)
CA (1) CA2282439C (de)
CO (1) CO4940469A1 (de)
ES (1) ES2384551T3 (de)
NZ (1) NZ510991A (de)
WO (1) WO1998038984A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
KR100743287B1 (ko) * 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
DE60012718T2 (de) * 1999-04-09 2005-10-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prognose von ptp lar vermittelten krankheiten
KR20020029419A (ko) 1999-07-07 2002-04-18 다비드 에 질레스 퀴나졸린 유도체
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
EP1259234B9 (de) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
AU7425801A (en) 2000-06-24 2002-01-08 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
WO2002002534A1 (en) * 2000-07-03 2002-01-10 Astrazeneca Ab Quinazolines with therapeutic use
AU2001277099B2 (en) * 2000-07-24 2006-08-31 Pharmacia & Upjohn Company Llc Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
CA2417813A1 (en) * 2000-08-10 2002-02-21 Delsys Pharmaceutical Corporation Improved solid pharmaceutical dosage formulation of hydrophobic drugs
US20050158271A1 (en) * 2000-10-11 2005-07-21 Lee Sang C. Pharmaceutical applications of hydrotropic polymer micelles
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002069936A2 (en) * 2001-03-02 2002-09-12 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition of ibuprofen
US6912582B2 (en) 2001-03-30 2005-06-28 Microsoft Corporation Service routing and web integration in a distributed multi-site user authentication system
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
JP2005514368A (ja) * 2001-11-21 2005-05-19 スージェン・インコーポレーテッド インドリノン誘導体を含む医薬製剤
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
RS63204A (sr) * 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
JP2005528344A (ja) * 2002-02-15 2005-09-22 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー インドリノン誘導体の製造法
CN1326569C (zh) * 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 含有水溶性纤维素衍生物的iressa药物制剂
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1500652A4 (de) 2002-04-26 2006-05-03 Nippon Shinyaku Co Ltd Chinazolinderivat und arzneimittel
AU2003296984A1 (en) * 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
RU2356896C2 (ru) 2003-04-16 2009-05-27 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
ES2279361T3 (es) 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
EP1682126B1 (de) * 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP5001150B2 (ja) * 2004-06-08 2012-08-15 ファミリーズ オブ スパイナル マスキュラー アトロフィー 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
KR100915481B1 (ko) * 2004-11-09 2009-09-03 에프. 호프만-라 로슈 아게 아미노퀴나졸린 화합물
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
MX2007011250A (es) * 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
ES2354457T3 (es) 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007100880A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
CA2659376C (en) * 2006-08-01 2014-10-14 Jasbir Singh 2,4-diaminoquinazolines for spinal muscular atrophy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
EP2200613B1 (de) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazin-derivate und ihre verwendungen
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5359333B2 (ja) * 2009-02-05 2013-12-04 ゼリア新薬工業株式会社 コロソリン酸含有水性液剤
CA2752885A1 (en) * 2009-02-27 2010-09-02 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and methods of use thereof
EP2473487B1 (de) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Chinazoline als kaliumionenkanalhemmer
CA2780292A1 (en) * 2009-11-10 2011-05-19 Celgene Corporation Nanosus pens ion of a poorly soluble drug made by microfluidization process
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102716103B (zh) * 2012-07-02 2013-12-18 西安力邦制药有限公司 2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN103837615B (zh) * 2014-02-15 2015-05-20 青岛农业大学 一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3824296B1 (de) 2018-07-20 2026-04-01 Lipocine Inc. Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
EP4563150A3 (de) 2019-05-13 2025-07-23 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs
CA3180971A1 (en) * 2020-04-22 2021-10-28 Scienture, Inc. Long-acting bupivacaine microsphere formulations
CN113398067B (zh) * 2021-07-19 2022-08-16 宁波三生生物科技股份有限公司 一种四烯雌酮注射液及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970725A (en) 1972-09-26 1976-07-20 Dai Nippon Toryo Co., Ltd. Powdery coating composition and process for preparing the same
US3850939A (en) 1973-02-20 1974-11-26 Parke Davis & Co 5-nitro-2-thiazolylthiopyridine,1-oxides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59190967A (ja) * 1983-04-15 1984-10-29 Hokuriku Seiyaku Co Ltd １−（２，６−ジフルオロフエニル）−２−インドリノン誘導体
JPS61167616A (ja) * 1985-01-22 1986-07-29 Adeka Argus Chem Co Ltd 放射線増感剤
DE69001809T2 (de) 1990-03-19 1994-01-05 Agfa Gevaert Nv Elektronenacceptoren enthaltende Photomaterialien.
AU8641991A (en) * 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH11507052A (ja) 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
EP0831795A2 (de) 1995-06-07 1998-04-01 Sugen, Inc. Phosphatase inhibitoren
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Also Published As

Publication number Publication date
US6696482B2 (en) 2004-02-24
NZ510991A (en) 2002-11-26
EP1014953B1 (de) 2012-04-25
WO1998038984A3 (en) 1999-01-28
US6248771B1 (en) 2001-06-19
ES2384551T3 (es) 2012-07-06
US20010012844A1 (en) 2001-08-09
JP2001514626A (ja) 2001-09-11
CA2282439C (en) 2010-05-04
AU743024B2 (en) 2002-01-17
CO4940469A1 (es) 2000-07-24
HK1028548A1 (en) 2001-02-23
WO1998038984A2 (en) 1998-09-11
JP4713698B2 (ja) 2011-06-29
CA2282439A1 (en) 1998-09-11
EP1014953A2 (de) 2000-07-05
AU6680698A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
ATE216590T1 (de) Arzneimittelformulierungen für il-12
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
MY118151A (en) Pharmaceutical formulations containing voriconazole.
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FI960032L (fi) Farmaseuttisia koostumuksia vaikeasti liukenevia aktiiviaineita varten
BRPI9605663B8 (pt) Bis (resorcinil) triazinas.
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
FI963916L (fi) Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
SE8602723L (sv) Tiazoler, deras framstellning och farmaceutiska kompositioner innehallande dem
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
GEP20043377B (en) Pharmaceutical Complex
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico